Page 22 of 23

PA29.2-10 | Female Genital Tract — Case Study

CLINICAL SCENARIO

This assignment presents a real-world clinico-pathological scenario drawn from the female genital tract, requiring you to integrate clinical findings, gross and microscopic pathology, laboratory investigations, and disease mechanisms into a coherent diagnostic narrative.

You will analyse the case through a structured framework — formulating a differential diagnosis, predicting and interpreting pathological findings, selecting relevant investigations, applying staging/grading criteria, explaining pathogenesis, and discussing prognosis. The goal is to develop the reasoning skills of a clinician-pathologist, not to reproduce memorised facts.

Instructions

Read the clinical vignette carefully before you begin writing. Your response must follow the six scaffolded sections below in order. Each section has a guiding prompt — treat these as thinking aids, not rigid checklists.

Answer in continuous prose within each section (bullet lists may supplement, but should not replace, analytical paragraphs).
Integrate NMC CBME competencies PA29.2–PA29.10 as appropriate throughout your discussion.
Cite specific gross and microscopic features; vague statements ('the tissue looked abnormal') earn no marks.
Where investigations are discussed, explain what each finding means pathophysiologically — do not list tests without interpretation.
Staging must reference the current WHO/FIGO classification relevant to the diagnosis.
Word target: 600–900 words across all sections combined (excluding headings and the clinical vignette).
After submission, you will be assigned two peer submissions to review using the rubric provided. Complete peer reviews within 48 hours.

--- CLINICAL VIGNETTE ---
Mrs Kavitha R., a 28-year-old para 1 woman, presents to the gynaecology OPD with amenorrhoea of 14 weeks and persistent, severe nausea. Her last menstrual period was irregular. Urine pregnancy test is positive. On examination, uterine size corresponds to 20 weeks — larger than dates. Serum β-hCG is markedly elevated at 4,20,000 mIU/mL. Transvaginal ultrasound shows an enlarged uterus filled with heterogeneous echogenic material and multiple anechoic spaces in a 'snowstorm' pattern; no fetal pole or cardiac activity is identified. Both ovaries show multiple thin-walled cysts (theca-lutein cysts), each measuring 4–6 cm. Chest X-ray is normal. She undergoes suction evacuation; the evacuated material is sent for histopathological examination.

Length: 600–900 words

What to Submit

Section 1: Clinical Reasoning and Differential Diagnosis

Based on the clinical features — uterine size larger than dates, markedly elevated β-hCG, 'snowstorm' ultrasound appearance, absence of fetal pole, and bilateral theca-lutein cysts — formulate a ranked differential diagnosis. For each differential, briefly state the key supporting and refuting features from this case. Identify your primary diagnosis and justify it.

Section 2: Gross and Microscopic Pathological Findings

Describe the expected gross appearance of the evacuated uterine contents for your primary diagnosis. Then describe the key microscopic features you would expect on H&E-stained sections, including: villous architecture, trophoblastic proliferation (type and distribution), stromal changes, and any cytological atypia. Clearly distinguish the features that differentiate your primary diagnosis from the closest alternative on your differential. Reference the relevant PA29 competencies.

Section 3: Investigations and Tumour Markers

List the essential investigations required for definitive diagnosis, staging, and baseline assessment in this patient. For each investigation, explain what specific result you expect and what that result tells you about disease extent or biology (e.g., why is β-hCG both a diagnostic and a monitoring marker? Why is a chest X-ray — and when a CT chest — necessary?). Include histopathological, biochemical, and imaging investigations.

Section 4: Classification, Staging, and Grading

Using the current WHO classification of gestational trophoblastic disease and the FIGO anatomical staging / prognostic scoring system (2000, revised), classify this patient's disease. If the histology reveals a specific subtype, name it and describe its defining diagnostic criteria. Assign a provisional FIGO stage and calculate a prognostic score range based on the information available, identifying which variables are known and which require further workup.

Section 5: Pathogenesis

Explain the molecular and cellular pathogenesis of the primary diagnosis, covering: the origin of the abnormal conceptus (fertilisation event), the role of abnormal trophoblastic proliferation, the mechanism by which β-hCG drives theca-lutein cyst formation, and how the disease may progress toward malignant gestational trophoblastic neoplasia (GTN). Where relevant, mention genetic/chromosomal events (e.g., ploidy, parental genomic imprinting).

Section 6: Prognosis, Follow-up, and Complications

Describe the expected prognosis for this patient after successful suction evacuation. Outline the standard post-evacuation surveillance protocol (β-hCG monitoring schedule, contraception advice, timing of next pregnancy). Identify the clinical/laboratory features that would indicate malignant transformation to persistent GTD or choriocarcinoma and necessitate chemotherapy. Comment briefly on the prognosis of GTN if treatment is required.

Grading Rubric — Female Genital Tract Case Study Rubric

Criterion	Points	Full-marks descriptor
Differential Diagnosis and Clinical Reasoning — assesses ability to construct a ranked differential using clinical, biochemical, and imaging evidence; quality of supporting/refuting argument; accuracy of primary diagnosis identification	6 pts	Accurate, ranked differential with ≥3 plausible diagnoses; clear evidence-based justification for each; primary diagnosis correct with compelling reasoning integrating all key clinical features (uterine size, β-hCG level, snowstorm ultrasound, theca-lutein cysts)
Gross and Microscopic Pathological Description — assesses precision and accuracy of morphological description; ability to distinguish histological subtypes; use of correct pathological terminology (PA29.9, PA29.10)	7 pts	Accurate, detailed gross description (grape-like vesicles, no fetal parts for complete mole); precise microscopic description including villous hydrops, circumferential trophoblastic hyperplasia, cistern formation, absent/avascular stroma, and cytological features; clearly differentiates complete from partial mole using morphological criteria
Investigations and Marker Interpretation — assesses selection of appropriate investigations, interpretation of expected results, and understanding of β-hCG as a diagnostic, monitoring, and prognostic marker	5 pts	Selects all essential investigations (serial quantitative β-hCG, chest X-ray ± CT, histopathology/p57 IHC, thyroid function, blood group); correctly interprets expected results with pathophysiological explanation for each; explains β-hCG monitoring rationale and threshold for further imaging
Classification, Staging, and Grading — assesses correct application of WHO histological classification and FIGO staging/prognostic scoring system; accuracy of provisional score calculation	5 pts	Correctly names WHO subtype with diagnostic criteria; assigns accurate FIGO anatomical stage; calculates FIGO prognostic score with correct variable identification (β-hCG level, uterine size, age, antecedent pregnancy type, interval); identifies variables requiring further workup; explains clinical implications of the score
Pathogenesis — assesses depth of mechanistic explanation; accuracy of chromosomal/fertilisation events; understanding of trophoblastic biology and malignant progression potential	4 pts	Accurately explains the androgenetic diploid origin of complete mole (two paternal haploid sets, no maternal contribution); describes the fertilisation event (dispermy or duplication of a single sperm into an empty ovum); explains abnormal trophoblastic proliferation driven by lack of maternal genomic imprinting; correctly links β-hCG excess to luteinisation; describes malignant progression pathway to invasive mole/choriocarcinoma
Prognosis, Surveillance, and Complication Recognition — assesses accuracy of post-molar surveillance protocol, ability to identify features of malignant transformation, and understanding of GTN prognosis	3 pts	Correctly describes β-hCG surveillance schedule (weekly until normal × 3, then monthly × 6–12 months); recommends reliable contraception (OCP preferred) and 12-month delay before next pregnancy; accurately identifies WHO criteria for persistent GTD requiring chemotherapy (plateau/rise in β-hCG, histological GTN, metastasis); gives accurate prognosis for low-risk GTN (>95% cure with single-agent chemotherapy)

PEER REVIEW

You will review two of your peers' submissions using the rubric above. For each criterion:
1. Read the criterion description carefully and apply it to your peer's response — do not award marks based on general impression.
2. Select the rating level that best matches the quality of your peer's response and enter the corresponding points.
3. Write a brief justification (2–4 sentences) for each criterion score: state what the submission did well and what was missing or inaccurate.
4. In the overall comment box, write 3–5 sentences summarising the strongest aspect of the submission and the single most important area for improvement.
5. Be specific: reference particular sentences or claims in your peer's submission.
6. Tone must be constructive and professional. Avoid purely negative commentary; identify what would have made a weak section stronger.
7. Peer review scores count toward your own assignment grade — cursory or unjustified reviews will be penalised.